United States· US:64842-0727_130350a1-2b88-4253-99ea-9fbc0d066ea7
INQOVI
A medicinal product containing cedazuridine; decitabine, registered in United States by Taiho Pharmaceutical Co., Ltd..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CEDAZURIDINE; DECITABINE
- Manufacturer
- Taiho Pharmaceutical Co., Ltd.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1164842-0727-9
- ndc1164842072791 BLISTER PACK in 1 CARTON (64842-0727-9) / 5 TABLET, FILM COATED in 1 BLISTER PACK
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cedazuridine; decitabine in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINAQOVIOtsuka Pharmaceutical Netherlands B.V., Amsterdam
- PolandInaqoviOtsuka Pharmaceutical Netherlands B.V.
- CanadaINQOVITAIHO PHARMA CANADA, INC.
- SpainINAQOVI 35 MG/100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAOtsuka Pharmaceutical Netherlands B.V.
- FinlandInaqoviOtsuka Pharmaceutical Netherlands B.V.
- United KingdomInaqovi 35mg/100mg tabletsOtsuka Pharmaceuticals (U.K.) Ltd
- IrelandInaqovi 35 mg/100 mg film-coated tabletsOtsuka Pharmaceutical Netherlands B.V.
- IcelandInaqoviOtsuka Pharmaceutical Netherlands B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inaqovi
- Liechtenstein · Inaqovi
- Norway · Inaqovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/00ac915f-a5f9-4d28-9c98-03e9e44890dc GET /v1/drugs/00ac915f-a5f9-4d28-9c98-03e9e44890dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100; 35",
"substance": "CEDAZURIDINE; DECITABINE",
"productndc": "64842-0727",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1",
"application_number": "NDA212576",
"marketing_category": "NDA"
}See everything about cedazuridine; decitabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.